NO20045153L - Stabilt, fast medisinpreparat for oral administrasjon - Google Patents

Stabilt, fast medisinpreparat for oral administrasjon

Info

Publication number
NO20045153L
NO20045153L NO20045153A NO20045153A NO20045153L NO 20045153 L NO20045153 L NO 20045153L NO 20045153 A NO20045153 A NO 20045153A NO 20045153 A NO20045153 A NO 20045153A NO 20045153 L NO20045153 L NO 20045153L
Authority
NO
Norway
Prior art keywords
ramosetron
ester
pharmaceutically acceptable
acid
acceptable salt
Prior art date
Application number
NO20045153A
Other languages
English (en)
Inventor
Katsuhiro Masaki
Akio Sugihara
Takehiko Yasuji
Akito Nishida
Akira Niwa
Yutaka Atsuta
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of NO20045153L publication Critical patent/NO20045153L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Preparat med ramosetron eller et farmasøytisk akseptabelt salt av dette er, spesielt med lavt innhold, stabilt under betingelser med temperatur/fuktighet. Preparatet er en stabil, fast medisinsk blanding for oral administrasjon, som inneholder ramosetron eller et farmasøytisk akseptabelt salt av dette, og én eller flere forbindelser valgt blant alifafiske karboksylsyrer eller estere derav, hydroksykarboksylsyrer eller estere derav, sure aminosyrer, enolsyrer, aromatiske karboksyforbindelser eller estere derav, og karboksylerte polymere substanser. Det beskrives også en fremgangsmåte for å stabilisere den medisinske blanding, og et terapeutisk middel for diaré-type irritabelt tarmsyndrom, som inneholder som aktiv ingrediens enten ramosetronhydrogenklorid i en mengde på 0,002 til 0,02 mg som daglig dose, eller en ekvimolar mengde ramosetron eller et farmasøytisk akseptabelt annet salt av dette.
NO20045153A 2003-01-31 2004-11-25 Stabilt, fast medisinpreparat for oral administrasjon NO20045153L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003023500 2003-01-31
PCT/JP2004/000896 WO2004066998A1 (ja) 2003-01-31 2004-01-30 安定な経口用固形医薬組成物

Publications (1)

Publication Number Publication Date
NO20045153L true NO20045153L (no) 2005-02-04

Family

ID=32820728

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045153A NO20045153L (no) 2003-01-31 2004-11-25 Stabilt, fast medisinpreparat for oral administrasjon

Country Status (22)

Country Link
US (1) US7794748B2 (no)
EP (1) EP1588707B1 (no)
JP (1) JP3689104B2 (no)
KR (1) KR100633836B1 (no)
CN (1) CN100379416C (no)
AT (1) ATE420638T1 (no)
AU (1) AU2004208617B2 (no)
BR (1) BRPI0405221A (no)
CA (1) CA2488422C (no)
DE (1) DE602004019049D1 (no)
DK (1) DK1588707T3 (no)
ES (1) ES2319292T3 (no)
HK (1) HK1084582A1 (no)
IL (1) IL165371A (no)
MX (1) MXPA04012462A (no)
NO (1) NO20045153L (no)
NZ (1) NZ537448A (no)
PL (1) PL375181A1 (no)
PT (1) PT1588707E (no)
RU (1) RU2284819C2 (no)
WO (1) WO2004066998A1 (no)
ZA (2) ZA200409537B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
US7358270B2 (en) * 2004-01-30 2008-04-15 Astellas Pharma Inc. Treating agent for irritable bowel syndrome
CN102813635A (zh) * 2006-08-10 2012-12-12 武田药品工业株式会社 药物组合物
WO2008032726A1 (fr) 2006-09-15 2008-03-20 Astellas Pharma Inc. Composition pharmaceutique solide pour administration orale comprenant du ramosétron optiquement stable
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
EP2555828B1 (en) * 2010-04-09 2017-07-19 Unilever PLC, a company registered in England and Wales under company no. 41424 Oral care compositions
NZ613167A (en) 2010-12-16 2015-09-25 Univ Texas Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds
US9364433B2 (en) 2011-04-28 2016-06-14 Borje S. Andersson Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
EP3272345B1 (en) 2015-03-19 2019-10-16 Daiichi Sankyo Company, Limited Solid preparation containing antioxidant agent
EP3437639A1 (en) * 2015-03-19 2019-02-06 Daiichi Sankyo Company, Limited Solid preparation containing colorant
CN106937946B (zh) * 2016-01-05 2020-05-12 山东诚创医药技术开发有限公司 盐酸雷莫司琼泡腾片及其制备方法
CN107224430A (zh) * 2016-03-25 2017-10-03 江苏奥赛康药业股份有限公司 一种含盐酸雷莫司琼的药物组合物
KR102349971B1 (ko) * 2016-04-27 2022-01-12 주식회사 엘지생활건강 폴리다틴 또는 이의 약학적으로 허용 가능한 염의 광 안정화용 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB759081A (en) * 1954-04-15 1956-10-10 John Holroyd And Company Ltd Improvements relating to machines for the production of coated tablets and the like
US4067974A (en) * 1976-01-21 1978-01-10 The Purdue Frederick Company Stabilized solid form choline salicylate compositions
GB8629567D0 (en) 1986-12-10 1987-01-21 Boots Co Plc Therapeutic agents
US5223508A (en) * 1988-12-27 1993-06-29 Kirin Beer Kabushiki Kaisha Pyridyl carboximidamide compounds useful in treating blood pressure
US5344927A (en) * 1989-02-02 1994-09-06 Yamanouchi Pharmaceutical Co., Ltd. Tetrahydrobenzimidazole derivatives and pharmaceutical compositions containing same
US5107887A (en) 1990-12-03 1992-04-28 The Aro Corporation High pressure fluid regulator
JPH0565226A (ja) * 1991-09-10 1993-03-19 Taisho Pharmaceut Co Ltd アミノアルキルピリジルオキシ誘導体の安定化組成物
TWI285644B (en) * 1997-07-11 2007-08-21 Toray Industries A stable pharmaceutical composition containing a derivative of 4,5-epoxymorphinan and a water-soluble antioxidant, an oil-soluble antioxidant, a synergist, a sugar and a surfactant
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
PT1038525E (pt) * 1997-10-20 2004-11-30 Dainippon Pharmaceutical Co Composicoes farmaceuticas estabilizadas
PL200645B1 (pl) * 1999-08-04 2009-01-30 Astellas Pharma Inc Trwała kompozycja farmaceutyczna do stosowania doustnego, trwała tabletka farmaceutyczna do stosowania doustnego, sposób wytwarzania trwałej kompozycji farmaceutycznej oraz zastosowanie żółtego tlenku żelazowego lub czerwonego tlenku żelazowego do stabilizowania preparatu
AU6280900A (en) 1999-08-09 2001-03-05 Pharmacia & Upjohn S.P.A. Formulations for parenteral use of estramustine phosphate and albumin
DE19941997A1 (de) * 1999-09-02 2001-03-08 Gunther Meinhardt Voss Verfahren und Vorrichtung zur Herstellung einer Tablette o. dgl.
KR100863146B1 (ko) 2000-07-17 2008-10-14 아스텔라스세이야쿠 가부시키가이샤 경구 흡수 개선 의약 조성물
US6566369B2 (en) * 2000-07-26 2003-05-20 Solvay Pharmaceuticals Gmbh Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
RU2245136C2 (ru) * 2001-07-27 2005-01-27 Яманоути Фармасьютикал Ко., ЛТД Композиция, включающая тонкодисперсные частицы с замедленным высвобождением для быстроразлагающихся в щечной полости таблеток, и способ ее получения
GB0119012D0 (en) * 2001-08-03 2001-09-26 Strakan Group Plc Transdermal delivery of drugs
US20030143548A1 (en) 2002-01-28 2003-07-31 Camilleri Michael L. Predicting patient responsiveness to serotonergic therapy
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
US7358270B2 (en) 2004-01-30 2008-04-15 Astellas Pharma Inc. Treating agent for irritable bowel syndrome

Also Published As

Publication number Publication date
EP1588707B1 (en) 2009-01-14
ATE420638T1 (de) 2009-01-15
KR100633836B1 (ko) 2006-10-13
KR20050044772A (ko) 2005-05-12
ZA200506503B (en) 2006-12-27
DK1588707T3 (da) 2009-03-09
DE602004019049D1 (de) 2009-03-05
AU2004208617A1 (en) 2004-08-12
ZA200409537B (en) 2006-10-25
IL165371A (en) 2009-08-03
PT1588707E (pt) 2009-03-27
AU2004208617B2 (en) 2007-09-13
CN100379416C (zh) 2008-04-09
ES2319292T3 (es) 2009-05-06
RU2284819C2 (ru) 2006-10-10
AU2004208617A2 (en) 2004-08-12
PL375181A1 (en) 2005-11-28
MXPA04012462A (es) 2005-02-24
US20050026981A1 (en) 2005-02-03
CA2488422C (en) 2008-08-19
US7794748B2 (en) 2010-09-14
EP1588707A4 (en) 2006-03-15
CN1723021A (zh) 2006-01-18
JP3689104B2 (ja) 2005-08-31
RU2004136181A (ru) 2005-08-10
NZ537448A (en) 2008-06-30
WO2004066998A1 (ja) 2004-08-12
CA2488422A1 (en) 2004-08-12
HK1084582A1 (en) 2006-08-04
BRPI0405221A (pt) 2005-03-15
EP1588707A1 (en) 2005-10-26
JPWO2004066998A1 (ja) 2006-05-18
IL165371A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
HK1084582A1 (en) Stable solid medicinal composition for oral administration
BG106439A (en) Pharmaceutical composition of improved solubility and oral absorptivity, containing benzamide derivative
ATE500818T1 (de) Kalziumatorvastatin enthaltende arzneiformulierung
EA200702416A1 (ru) Фармацевтическая композиция, содержащая симвастатин и эзетимиб
HU224964B1 (en) Process for stabilization of naloxone and stable pharmaceutical compositions containing naloxone
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
JP2006520346A (ja) 制御放出システム
SE9901573D0 (sv) New compounds
ES2391812T3 (es) Composiciones estables de rosuvastatina
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
ES2378091T3 (es) Composiciones farmacéuticas que contienen leflunomida
SE9901572D0 (sv) New compounds
NO323556B1 (no) Forbindelser, farmasoytiske preparater som omfatter forbindelsene, og anvendelse av forbindelsene ved fremstilling av antibakterielle medikamenter.
NO20015666D0 (no) Umiddelbar frigivelses medisinske sammensetninger for oral anvendelse
WO2003070153A3 (en) Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives
PT97164A (pt) Processo para a estabilizacao de uma preparacao que contenham o composto 4-etil-2-hidroxi-imino-5-nitro-3-hexenamida e de composicoes farmaceuticas que o contenham
JP2014516946A (ja) エザチオスタットとの賦形剤適合性
WO2014195900A2 (es) Composiciones farmacéuticas orales para uso en dislipidemias
JPH107570A (ja) パーキンソン病予防・治療剤
CY1114106T1 (el) Σταθερες φαρμακευτικες συνθεσεις που περιεχουν 7-υποκατεστημενα-3,5-διυδροξυεπτανοϊκα οξεα ή 7-υποκατεστημενα-3,5-διυδροξυεπτενοϊκα οξεα
TH45966A3 (th) แอนตี้ฮิสตามีน ไซรัปที่เสถียร

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application